Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?

Croat Med J. 2024 Oct 31;65(5):454-456. doi: 10.3325/cmj.2024.65.454.
No abstract available